We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Processa Pharmaceuticals Inc (PCSA) USD0.0001

Sell:$1.71 Buy:$1.79 Change: $0.1 (5.88%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Change: $0.1 (5.88%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Change: $0.1 (5.88%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).

Contact details

7380 Coca Cola Dr Ste 106
United States
+1 (443) 7763133

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.89 million
Shares in issue:
2.86 million
United States
US dollar

Key personnel

  • George Ng
    Chief Executive Officer, Director
  • Wendy Guy
    Founder, Chief Administrative Officer
  • Sian Bigora
    Chief Development Officer, Founder
  • James Stanker
    Chief Financial Officer
  • David Young
    President - Research and Development, Director
  • Patrick Lin
    Chief Business and Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.